FindTrial
Sign In

Merestinib

DRUG8 trials

Sponsors

Eli Lilly and Company, Dana-Farber Cancer Institute, Jacqueline Garcia, MD, University of Utah

Conditions

Advanced CancerBiliary Tract CancerBiliary Tract CarcinomaBone MetastasesBreast CancerBreast Cancer (HR+HER2-)Carcinoma, Non-Small-Cell LungCholangiocarcinoma

Phase 1

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
CompletedNCT02745769
Eli Lilly and CompanyAdvanced Cancer, Colorectal Cancer, Mantle Cell Lymphoma
Start: 2016-10-21End: 2019-01-22Updated: 2019-03-05
A Study of Merestinib (LY2801653) in Healthy Participants
CompletedNCT02779738
Eli Lilly and CompanyHealthy
Start: 2016-05-31End: 2016-08-31Updated: 2016-08-29
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
CompletedNCT02791334
Eli Lilly and CompanyBreast Cancer (HR+HER2-), Cutaneous Melanoma, Microsatellite Instability-High (MSI-H) Solid Tumors +2
Start: 2016-06-29End: 2024-06-27Updated: 2024-09-27
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
CompletedNCT03027284
Eli Lilly and CompanyAdvanced Cancer, Biliary Tract Carcinoma, Cholangiocarcinoma +4
Start: 2017-02-03End: 2020-03-17Updated: 2020-05-19
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
CompletedNCT03125239
Jacqueline Garcia, MDRefractory Adult Acute Myeloid Leukemia, Relapsed Adult Acute Myeloid Leukemia
Start: 2017-08-10End: 2020-06-01Updated: 2020-06-30
Merestinib on Bone Metastases in Subjects With Breast Cancer
TerminatedNCT03292536
University of UtahBone Metastases, Breast Cancer
Start: 2018-01-11End: 2019-06-24Updated: 2021-01-08

Phase 2

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Active, not recruitingNCT02711553
Eli Lilly and CompanyAdvanced Cancer, Biliary Tract Cancer, Metastatic Cancer
Start: 2016-05-19End: 2026-12-31Updated: 2025-08-03
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
TerminatedNCT02920996
Dana-Farber Cancer InstituteCarcinoma, Non-Small-Cell Lung, Solid Tumor
Start: 2016-11-11End: 2023-10-31Updated: 2024-04-11

Related Papers

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
2023-01-1219 citations
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
2021-10-0157 citations
Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
Cancer Medicine2021-09-097 citations
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Clinical Cancer Research2020-11-2345 citations
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.
Journal of Clinical Oncology2020-02-0129 citations
Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents
Cancer Research2018-07-012 citations
Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054
Cancer Research2018-07-01
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
Oncotarget2018-02-1349 citations
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
2017-11-2924 citations
Abstract 1823: Characterization of the anti-angiogenic properties of merestinib (LY2801653), an oncokinase inhibitor
Cancer Research2017-07-011 citations
Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model
Cancer Research2017-07-01
Abstract 528: Evaluation of single agent merestinib (LY2801653) or emibetuzumab (LY2875358) and the combination in a xenograft tumor model bearing MET exon 14 skipping
Cancer Research2017-07-01
Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.
Journal of Clinical Oncology2017-02-018 citations